Natera
NTRA
$267.76
-0.70%
Natera, Inc. is a diagnostic and research company that leverages proprietary molecular and bioinformatics technology to develop and commercialize advanced genetic testing products, including the Panorama non-invasive prenatal test (NIPT), Horizon carrier screening, Signatera molecular residual disease (MRD) test for cancer recurrence monitoring, and Prospera for organ transplant rejection assessment. As a leader in the liquid biopsy and reproductive health diagnostics space, Natera has established a strong competitive moat through its high-sensitivity assays and extensive clinical validation, positioning it as a key player in the rapidly growing precision medicine market. The current investor narrative centers on the company's accelerating revenue growth, driven by the expanding adoption of Signatera in oncology and recent positive clinical data, alongside its path toward sustained profitability, which has fueled a significant re-rating of the stock over the past year. However, debates persist regarding the sustainability of its growth trajectory, competitive pressures from emerging players, and the valuation premium it commands relative to peers.…
NTRA
Natera
$267.76
Related headlines
Investment Opinion: Should I buy NTRA Today?
Based on the analysis, Natera is rated a Buy, supported by its accelerating revenue growth, improving profitability, and strong analyst consensus. The average analyst target of $282.86 implies a 5.6% upside, while the high target of $330 suggests 23.2% upside, indicating that the stock is expected to appreciate over the next 12 months. The thesis is that Natera's leadership in MRD testing and expanding adoption of its products will drive sustained growth, eventually leading to profitability.
Sign up to view all
NTRA 12-Month Price Forecast
The AI assessment leans bullish, driven by Natera's accelerating revenue growth and improving profitability metrics. The company's leadership in the high-growth MRD market and strong gross margins support the thesis. However, the high valuation and beta warrant caution, and the stance would be upgraded if the company achieves sustained profitability or downgraded if growth decelerates significantly. Key factors to watch include quarterly revenue growth rates, margin trends, and competitive developments.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $282.86 and implied upside of +5.6% versus the current price.
Average Target
$282.86
0 analysts
Implied Upside
+5.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$193 - $330
Analyst target range
The target price range spans from a low of $193.00 to a high of $330.00, representing a wide spread of $137, which signals significant uncertainty about the company's future performance. The high target of $330 implies an upside of 23.2% and likely assumes continued strong adoption of Signatera, potential regulatory approvals, and sustained revenue growth of 30%+ over the next few years. The low target of $193 suggests a downside of 27.9%, which could materialize if competitive pressures intensify, reimbursement challenges arise, or growth decelerates more sharply than expected. The wide range reflects the high-beta nature of the stock and the binary outcomes associated with its oncology franchise. Given the recent positive momentum and strong analyst support, the consensus leans bullish, but investors should be mindful of the elevated valuation and the potential for volatility.
Bulls vs Bears: NTRA Investment Factors
Natera presents a compelling growth story with accelerating revenue, improving profitability, and strong analyst support, but it trades at a premium valuation that leaves little room for error. The bull case is supported by its market leadership in MRD testing and the potential for sustained 30%+ growth, while the bear case hinges on valuation risk and competitive threats. The most important tension is whether the company can maintain its growth trajectory and achieve profitability, as any slowdown could trigger a sharp de-rating. Currently, the evidence slightly favors the bull case given the strong momentum and analyst consensus, but investors must be prepared for high volatility.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 38.8% YoY to $696.6M, up from 33.1% in Q4 2025 and 27.9% in Q3 2025, demonstrating accelerating momentum. This growth is driven by strong adoption of Signatera and other tests, indicating a successful commercialization strategy.
- Improving Profitability Trajectory: Net loss narrowed to $85.1M in Q1 2026 from $100.9M in Q2 2025, and Q4 2025 actually posted a net profit of $47.3M. The company is trending toward sustained profitability, with positive free cash flow of $92M TTM, signaling improving operational efficiency.
- Strong Analyst Consensus: With 21 analysts, the consensus is a Strong Buy (mean rating 1.5), and the average target price of $282.86 implies ~5.6% upside from the current price of $267.76. The high target of $330 suggests 23.2% upside, reflecting confidence in the growth story.
- Market Leadership in MRD Testing: Signatera is a leading molecular residual disease test with extensive clinical validation, positioning Natera as a key player in the rapidly growing liquid biopsy market. This competitive moat supports sustained growth and pricing power.
Bearish
- High Valuation Premium: The PS ratio of 13.58x is over 200% above the industry average of 4.5x, implying the market is pricing in exceptional growth. Any disappointment in growth could lead to significant multiple compression.
- Unprofitable Operations: Despite improving trends, Natera still reported a net loss of $85.1M in Q1 2026, with a net margin of -9.0% TTM. The company's path to sustained profitability is not yet proven, and ongoing losses could pressure cash reserves.
- High Volatility and Beta: With a beta of 1.505, the stock is 50% more volatile than the market, amplifying downside risk. The 52-week range shows a max drawdown of -28.2%, indicating potential for significant losses in adverse conditions.
- Competitive Pressures: The liquid biopsy and diagnostics market is increasingly competitive, with emerging players and potential reimbursement challenges. If competitors gain traction or pricing pressures emerge, Natera's growth could decelerate.
NTRA Technical Analysis
Natera's stock has exhibited a powerful long-term uptrend, with a 1-year price change of +100.33%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $267.76 sits at approximately 87% of its 52-week range (low of $131.81 and high of $288.04), indicating that the stock is trading near its highs, which reflects strong momentum but also raises concerns about potential overextension. The stock's beta of 1.505 implies it is 50% more volatile than the market, amplifying both upside and downside moves, and its relative strength over the past year (82.14% vs. SPY) underscores its leadership position in the healthcare sector.
Beta
1.50
1.50x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$133-$288
Price range past year
Annual Return
+100.3%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +0.3% |
| 3m | +29.2% | +4.0% |
| 6m | +15.8% | +8.3% |
| 1y | +100.3% | +20.2% |
| ytd | +17.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is robustly accelerating, with Q1 2026 revenue of $696.64 million, representing a 38.82% year-over-year growth rate, up from 33.1% in Q4 2025 and 27.9% in Q3 2025. The company's oncology segment, which includes the Signatera MRD test, is a key growth driver, with product revenue of $693.87 million in the latest quarter, reflecting strong demand for its liquid biopsy offerings. This accelerating growth is a testament to the successful commercialization of its tests and expanding market penetration, though the company remains unprofitable on a GAAP basis, with a net loss of $85.09 million in Q1 2026, albeit narrower than the $100.94 million loss in Q2 2025, indicating a positive trend toward breakeven.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given Natera's negative net income (TTM net margin of -9.03%), the price-to-sales (PS) ratio is the most appropriate valuation metric, as earnings-based multiples are not meaningful. The trailing PS ratio stands at 13.58x, while the forward PS ratio (based on estimated revenue of $5.59 billion) is approximately 5.6x, implying that the market expects significant revenue growth to justify the current valuation. Compared to the industry average PS ratio of 4.5x (based on available data), Natera trades at a substantial premium of over 200%, reflecting its superior growth prospects and market leadership in MRD testing. Historically, the stock's PS ratio has ranged from 18x to 70x over the past five years, and the current 13.58x is near the lower end of that range, suggesting that despite the premium to peers, the valuation is more reasonable relative to its own history, potentially offering a favorable entry point for long-term investors.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, as Natera remains unprofitable with a net loss of $85.1M in Q1 2026, though narrowing from prior quarters. The company's negative net margin of -9.0% TTM and operating margin of -13.4% indicate ongoing cash burn, though positive free cash flow of $92M TTM provides some cushion. Debt-to-equity is low at 0.125, but the company's reliance on continued growth to justify its valuation is a key risk; if growth decelerates, the stock could face severe multiple compression. Revenue concentration in oncology and reproductive health tests also exposes the company to reimbursement and regulatory changes in these segments.